2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy

Cancer Letters

Volumn 355, Issue 2, 2014, Pages 176-183

  Zhang, Dongsheng ^a,b   Li, Juan ^a,b   Wang, Fengzhen ^c   Hu, Jun ^a,b   Wang, Shuwei ^a,b   Sun, Yueming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

2 Deoxy D glucose; Cancer; Glycolysis; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEOXYGLUCOSE; GLUCOSE;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CELL; CELL METABOLISM; DRUG MECHANISM; DRUG SAFETY; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; RISK ASSESSMENT; SHORT SURVEY; CELL DEATH; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TUMOR CELL LINE;

AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; DEOXYGLUCOSE; GLUCOSE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXIDATIVE STRESS;

EID: 84908220531     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.003     Document Type: Review

References (100)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Icard P., Lincet H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta 2012, 1826:423-433.
3. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
4. Zhao Y., Liu H., Liu Z., Ding Y., Ledoux S.P., Wilson G.L., Voellmy R., Lin Y., Lin W., Nahta R., Liu B., Fodstad O., Chen J., Wu Y., Price J.E., Tan M. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011, 71:4585-4597.
5. Xi H., Kurtoglu M., Liu H., Wangpaichitr M., You M., Liu X., Savaraj N., Lampidis T.J. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother. Pharmacol 2011, 67:899-910.
6. Zagorodna O., Martin S.M., Rutkowski D.T., Kuwana T., Spitz D.R., Knudson C.M. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines. Oncogene 2012, 31:2738-2749.
7. Ralser M., Wamelink M.M., Struys E.A., Joppich C., Krobitsch S., Jakobs C., Lehrach H. A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17807-17811.
8. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 2002, 1555:14-20.
9. Hamanaka R.B., Chandel N.S. Targeting glucose metabolism for cancer therapy. J. Exp. Med 2012, 209:211-215.
10. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
11. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., Royer R.E., Vander Jagt D.L., Semenza G.L., Dang C.V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2037-2042.
12. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
13. Priebe A., Tan L., Wahl H., Kueck A., He G., Kwok R., Opipari A., Liu J.R. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol. Oncol 2011, 122:389-395.
14. Swietach P., Vaughan-Jones R.D., Harris A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007, 26:299-310.
15. Annibaldi A., Widmann C. Glucose metabolism in cancer cells. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:466-470.
16. Golding J.P., Wardhaugh T., Patrick L., Turner M., Phillips J.B., Bruce J.I., Kimani S.G. Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy. Br. J. Cancer 2013, 109:976-982.
17. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
18. Mizutani S., Miyato Y., Shidara Y., Asoh S., Tokunaga A., Tajiri T., Ohta S. Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci 2009, 100:1680-1687.
19. Moreno-Sanchez R., Rodriguez-Enriquez S., Marin-Hernandez A., Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007, 274:1393-1418.
20. Sottnik J.L., Lori J.C., Rose B.J., Thamm D.H. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin. Exp. Metastasis 2011, 28:865-875.
21. Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med 2013, 3.
22. Dang C.V., Le A., Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res 2009, 15:6479-6483.
23. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
24. DiPaola R.S., Dvorzhinski D., Thalasila A., Garikapaty V., Doram D., May M., Bray K., Mathew R., Beaudoin B., Karp C., Stein M., Foran D.J., White E. Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate 2008, 68:1743-1752.
25. Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol 2014, 4:64.
26. Stein M., Lin H., Jeyamohan C., Dvorzhinski D., Gounder M., Bray K., Eddy S., Goodin S., White E., Dipaola R.S. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010, 70:1388-1394.
27. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest 2013, 123:3664-3671.
28. Perez-Sayans M., Suarez-Penaranda J.M., Pilar G.D., Barros-Angueira F., Gandara-Rey J.M., Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett 2011, 313:1-8.
29. Maher J.C., Savaraj N., Priebe W., Liu H., Lampidis T.J. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 2005, 30:e34-e39.
30. Semenza G.L. HIF-1: upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev 2010, 20:51-56.
31. Gottlieb E., Vousden K.H. p53 regulation of metabolic pathways. Cold Spring Harb. Perspect. Biol 2010, 2:a001040.
32. Liu J., Zhang C., Hu W., Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett 2013, pii: S0304-3835(13)00863-X. 10.1016/j.canlet.2013.12.025.
33. Schwartzenberg-Bar-Yoseph F., Armoni M., Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004, 64:2627-2633.
34. Kawauchi K., Araki K., Tobiume K., Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol 2008, 10:611-618.
35. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005, 65:177-185.
36. Sinthupibulyakit C., Ittarat W., St Clair W.H., St Clair D.K. p53 Protects lung cancer cells against metabolic stress. Int. J. Oncol 2010, 37:1575-1581.
37. Madan E., Gogna R., Bhatt M., Pati U., Kuppusamy P., Mahdi A.A. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011, 2:948-957.
38. Kurtoglu M., Maher J.C., Lampidis T.J. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid. Redox Signal 2007, 9:1383-1390.
39. Bandugula V.R. 2-Deoxy-D-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells. Tumour Biol 2013, 34:251-259. R.P.N.
40. Giammarioli A.M., Gambardella L., Barbati C., Pietraforte D., Tinari A., Alberton M., Gnessi L., Griffin R.J., Minetti M., Malorni W. Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. Int. J. Cancer 2012, 131:E337-E347.
41. Yamaguchi R., Janssen E., Perkins G., Ellisman M., Kitada S., Reed J.C. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS ONE 2011, 6:e24102.
42. Kim S.M., Yun M.R., Hong Y.K., Solca F., Kim J.H., Kim H.J., Cho B.C. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol. Cancer Ther 2013, 12:2145-2156.
43. Urakami K., Zangiacomi V., Yamaguchi K., Kusuhara M. Impact of 2-deoxy-D-glucose on the target metabolome profile of a human endometrial cancer cell line. Biomed. Res 2013, 34:221-229.
44. Robinson G.L., Dinsdale D., Macfarlane M., Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene 2012, 31:4996-5006.
45. Wood T.E., Dalili S., Simpson C.D., Hurren R., Mao X., Saiz F.S., Gronda M., Eberhard Y., Minden M.D., Bilan P.J., Klip A., Batey R.A., Schimmer A.D. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol. Cancer Ther 2008, 7:3546-3555.
46. Maher J.C., Wangpaichitr M., Savaraj N., Kurtoglu M., Lampidis T.J. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol. Cancer Ther 2007, 6:732-741.
47. Raez L.E., Papadopoulos K., Ricart A.D., Chiorean E.G., Dipaola R.S., Stein M.N., Rocha Lima C.M., Schlesselman J.J., Tolba K., Langmuir V.K., Kroll S., Jung D.T., Kurtoglu M., Rosenblatt J., Lampidis T.J. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol 2013, 71:523-530.
48. Scarbrough P.M., Mapuskar K.A., Mattson D.M., Gius D., Watson W.H., Spitz D.R. Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic. Biol. Med 2012, 52:436-443.
49. Fath M.A., Ahmad I.M., Smith C.J., Spence J., Spitz D.R. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism. Clin. Cancer Res 2011, 17:6206-6217.
50. Beneteau M., Zunino B., Jacquin M.A., Meynet O., Chiche J., Pradelli L.A., Marchetti S., Cornille A., Carles M., Ricci J.E. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc. Natl Acad. Sci. U.S.A. 2012, 109:20071-20076.
51. Boutros J., Almasan A. Combining 2-deoxy-D-glucose with electron transport chain blockers: a double-edged sword. Cancer Biol. Ther 2009, 8:1237-1238.
52. Fernandez-Gomez F.J., Pastor M.D., Garcia-Martinez E.M., Melero-Fernandez de Mera R., Gou-Fabregas M., Gomez-Lazaro M., Calvo S., Soler R.M., Galindo M.F., Jordan J. Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression. Neurobiol. Dis 2006, 24:296-307.
53. Wang X., Perez E., Liu R., Yan L.J., Mallet R.T., Yang S.H. Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells. Brain Res 2007, 1132:1-9.
54. Fath M.A., Diers A.R., Aykin-Burns N., Simons A.L., Hua L., Spitz D.R. Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol. Ther 2009, 8:1228-1236.
55. Csala M., Kereszturi E., Mandl J., Banhegyi G. The endoplasmic reticulum as the extracellular space inside the cell: role in protein folding and glycosylation. Antioxid. Redox Signal 2012, 16:1100-1108.
56. Schedin-Weiss S., Winblad B., Tjernberg L.O. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014, 281:46-62.
57. Breitling J., Aebi M. N-linked protein glycosylation in the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol 2013, 5:a013359.
58. Qin J.Z., Xin H., Nickoloff B.J. 2-deoxyglucose sensitizes melanoma cells to TRAIL-induced apoptosis which is reduced by mannose. Biochem. Biophys. Res. Commun 2010, 401:293-299.
59. Yoshida H. ER stress and diseases. FEBS J. 2007, 274:630-658.
60. Oyadomari S., Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004, 11:381-389.
61. Cheng Y., Diao D.M., Zhang H., Song Y.C., Dang C.X. Proliferation enhanced by NGF-NTRK1 signaling makes pancreatic cancer cells more sensitive to 2DG-induced apoptosis. Int. J. Med. Sci 2013, 10:634-640.
62. Schroder M., Kaufman R.J. ER stress and the unfolded protein response. Mutat. Res 2005, 569:29-63.
63. Tajiri S., Yano S., Morioka M., Kuratsu J., Mori M., Gotoh T. CHOP is involved in neuronal apoptosis induced by neurotrophic factor deprivation. FEBS Lett 2006, 580:3462-3468.
64. Andresen L., Skovbakke S.L., Persson G., Hagemann-Jensen M., Hansen K.A., Jensen H., Skov S. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation. J. Immunol 2012, 188:1847-1855.
65. Liu L., Chowdhury S., Fang X., Liu J.L., Srikant C.B. Attenuation of unfolded protein response and apoptosis by mReg2 induced GRP78 in mouse insulinoma cells. FEBS Lett 2014, 588:2016-2024.
66. Yu S.M., Kim S.J. Endoplasmic reticulum stress (ER-stress) by 2-deoxy-D-glucose (2DG) reduces cyclooxygenase-2 (COX-2) expression and N-glycosylation and induces a loss of COX-2 activity via a Src kinase-dependent pathway in rabbit articular chondrocytes. Exp. Mol. Med 2010, 42:777-786.
67. Ramirez-Peinado S., Alcazar-Limones F., Lagares-Tena L., El Mjiyad N., Caro-Maldonado A., Tirado O.M., Munoz-Pinedo C. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res 2011, 71:6796-6806.
68. Araya J., Hara H., Kuwano K. Autophagy in the pathogenesis of pulmonary disease. Intern. Med 2013, 52:2295-2303.
69. Chen N., Debnath J. Autophagy and tumorigenesis. FEBS Lett 2010, 584:1427-1435.
70. Melendez A., Neufeld T.P. The cell biology of autophagy in metazoans: a developing story. Development 2008, 135:2347-2360.
71. Hamasaki M., Yoshimori T. Where do they come from? Insights into autophagosome formation. FEBS Lett 2010, 584:1296-1301.
72. Klionsky D.J., Abeliovich H., Agostinis P., Agrawal D.K., Aliev G., Askew D.S., Baba M., Baehrecke E.H., Bahr B.A., Ballabio A., Bamber B.A., Bassham D.C., Bergamini E., Bi X., Biard-Piechaczyk M., Blum J.S., Bredesen D.E., Brodsky J.L., Brumell J.H., Brunk U.T., Bursch W., Camougrand N., Cebollero E., Cecconi F., Chen Y., Chin L.S., Choi A., Chu C.T., Chung J., Clarke P.G., Clark R.S., Clarke S.G., Clave C., Cleveland J.L., Codogno P., Colombo M.I., Coto-Montes A., Cregg J.M., Cuervo A.M., Debnath J., Demarchi F., Dennis P.B., Dennis P.A., Deretic V., Devenish R.J., Di Sano F., Dice J.F., Difiglia M., Dinesh-Kumar S., Distelhorst C.W., Djavaheri-Mergny M., Dorsey F.C., Droge W., Dron M., Dunn W.A., Duszenko M., Eissa N.T., Elazar Z., Esclatine A., Eskelinen E.L., Fesus L., Finley K.D., Fuentes J.M., Fueyo J., Fujisaki K., Galliot B., Gao F.B., Gewirtz D.A., Gibson S.B., Gohla A., Goldberg A.L., Gonzalez R., Gonzalez-Estevez C., Gorski S., Gottlieb R.A., Haussinger D., He Y.W., Heidenreich K., Hill J.A., Hoyer-Hansen M., Hu X., Huang W.P., Iwasaki A., Jaattela M., Jackson W.T., Jiang X., Jin S., Johansen T., Jung J.U., Kadowaki M., Kang C., Kelekar A., Kessel D.H., Kiel J.A., Kim H.P., Kimchi A., Kinsella T.J., Kiselyov K., Kitamoto K., Knecht E., Komatsu M., Kominami E., Kondo S., Kovacs A.L., Kroemer G., Kuan C.Y., Kumar R., Kundu M., Landry J., Laporte M., Le W., Lei H.Y., Lenardo M.J., Levine B., Lieberman A., Lim K.L., Lin F.C., Liou W., Liu L.F., Lopez-Berestein G., Lopez-Otin C., Lu B., Macleod K.F., Malorni W., Martinet W., Matsuoka K., Mautner J., Meijer A.J., Melendez A., Michels P., Miotto G., Mistiaen W.P., Mizushima N., Mograbi B., Monastyrska I., Moore M.N., Moreira P.I., Moriyasu Y., Motyl T., Munz C., Murphy L.O., Naqvi N.I., Neufeld T.P., Nishino I., Nixon R.A., Noda T., Nurnberg B., Ogawa M., Oleinick N.L., Olsen L.J., Ozpolat B., Paglin S., Palmer G.E., Papassideri I., Parkes M., Perlmutter D.H., Perry G., Piacentini M., Pinkas-Kramarski R., Prescott M., Proikas-Cezanne T., Raben N., Rami A., Reggiori F., Rohrer B., Rubinsztein D.C., Ryan K.M., Sadoshima J., Sakagami H., Sakai Y., Sandri M., Sasakawa C., Sass M., Schneider C., Seglen P.O., Seleverstov O., Settleman J., Shacka J.J., Shapiro I.M., Sibirny A., Silva-Zacarin E.C., Simon H.U., Simone C., Simonsen A., Smith M.A., Spanel-Borowski K., Srinivas V., Steeves M., Stenmark H., Stromhaug P.E., Subauste C.S., Sugimoto S., Sulzer D., Suzuki T., Swanson M.S., Tabas I., Takeshita F., Talbot N.J., Talloczy Z., Tanaka K., Tanida I., Taylor G.S., Taylor J.P., Terman A., Tettamanti G., Thompson C.B., Thumm M., Tolkovsky A.M., Tooze S.A., Truant R., Tumanovska L.V., Uchiyama Y., Ueno T., Uzcategui N.L., van der Klei I., Vaquero E.C., Vellai T., Vogel M.W., Wang H.G., Webster P., Wiley J.W., Xi Z., Xiao G., Yahalom J., Yang J.M., Yap G., Yin X.M., Yoshimori T., Yu L., Yue Z., Yuzaki M., Zabirnyk O., Zheng X., Zhu X., Deter R.L. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008, 4:151-175.
73. Shi Z., Li C.Y., Zhao S., Yu Y., An N., Liu Y.X., Wu C.F., Yue B.S., Bao J.K. A systems biology analysis of autophagy in cancer therapy. Cancer Lett 2013, 337:149-160.
74. Zhou S., Zhao L., Kuang M., Zhang B., Liang Z., Yi T., Wei Y., Zhao X. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. Cancer Lett 2012, 323:115-127.
75. Mei Y., Thompson M.D., Cohen R.A., Tong X. Autophagy and oxidative stress in cardiovascular diseases. Biochim. Biophys. Acta 2014, http://dx.doi.org/10.1016/j.bbadis.2014.05.005.
76. Yorimitsu T., Nair U., Yang Z., Klionsky D.J. Endoplasmic reticulum stress triggers autophagy. J. Biol. Chem 2006, 281:30299-30304.
77. Ciechomska I.A., Gabrusiewicz K., Szczepankiewicz A.A., Kaminska B. Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine a-induced cell death. Oncogene 2013, 32:1518-1529.
78. Liu L.L., Long Z.J., Wang L.X., Zheng F.M., Fang Z.G., Yan M., Xu D.F., Chen J.J., Wang S.W., Lin D.J., Liu Q. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol. Cancer Res 2013, 11:1326-1336.
79. Tanida I., Ueno T., Kominami E. LC3 and Autophagy. Methods Mol. Biol 2008, 445:77-88.
80. Ben Sahra I., Tanti J.F., Bost F. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010, 6:670-671.
81. Kang R., Zeh H.J., Lotze M.T., Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011, 18:571-580.
82. Ben Sahra I., Laurent K., Giuliano S., Larbret F., Ponzio G., Gounon P., Le Marchand-Brustel Y., Giorgetti-Peraldi S., Cormont M., Bertolotto C., Deckert M., Auberger P., Tanti J.F., Bost F. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010, 70:2465-2475.
83. Kurtoglu M., Gao N., Shang J., Maher J.C., Lehrman M.A., Wangpaichitr M., Savaraj N., Lane A.N., Lampidis T.J. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther 2007, 6:3049-3058.
84. Wu H., Zhu H., Liu D.X., Niu T.K., Ren X., Patel R., Hait W.N., Yang J.M. Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res 2009, 69:2453-2460.
85. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., De Young L.R., Lampidis T.J. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004, 64:31-34.
86. Papathanassiu A.E., MacDonald N.J., Emlet D.R., Vu H.A. Antitumor activity of efrapeptins, alone or in combination with 2-deoxyglucose, in breast cancer in vitro and in vivo. Cell Stress Chaperones 2011, 16:181-193.
87. Gu Y., Qi C., Sun X., Ma X., Zhang H., Hu L., Yuan J., Yu Q. Arctigenin preferentially induces tumor cell death under glucose deprivation by inhibiting cellular energy metabolism. Biochem. Pharmacol 2012, 84:468-476.
88. Olney K.E., Du J., van 't Erve T.J., Witmer J.R., Sibenaller Z.A., Wagner B.A., Buettner G.R., Cullen J.J. Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicity. Free Radic. Res 2013, 47:154-163.
89. Chuang J.H., Chou M.H., Tai M.H., Lin T.K., Liou C.W., Chen T., Hsu W.M., Wang P.W. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth. Int. J. Biochem. Cell Biol 2013, 45:944-951.
90. Cheong J.H., Park E.S., Liang J., Dennison J.B., Tsavachidou D., Nguyen-Charles C., Wa Cheng K., Hall H., Zhang D., Lu Y., Ravoori M., Kundra V., Ajani J., Lee J.S., Ki Hong W., Mills G.B. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther 2011, 10:2350-2362.
91. Wangpaichitr M., Savaraj N., Maher J., Kurtoglu M., Lampidis T.J. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol. Cancer Ther 2008, 7:1506-1513.
92. Kennedy C.R., Tilkens S.B., Guan H., Garner J.A., Or P.M., Chan A.M. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. Cancer Lett 2013, 336:299-306.
93. Zhang F., Aft R.L. Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J. Cancer Res. Ther 2009, 5(Suppl. 1):S41-S43.
94. Liu H., Hu Y.P., Savaraj N., Priebe W., Lampidis T.J. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 2001, 40:5542-5547.
95. Minor R.K., Smith D.L., Sossong A.M., Kaushik S., Poosala S., Spangler E.L., Roth G.S., Lane M., Allison D.B., de Cabo R., Ingram D.K., Mattison J.A. Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol. Appl. Pharmacol 2010, 243:332-339.
96. Sandoval D.A., Ryan K.K., de Kloet A.D., Woods S.C., Seeley R.J. Female rats are relatively more sensitive to reduced lipid versus reduced carbohydrate availability. Nutr. Diab 2012, 2:e27.
97. Yamaguchi R., Perkins G. Finding a Panacea among combination cancer therapies. Cancer Res 2012, 72:18-23.
98. Dwarakanath B.S., Singh D., Banerji A.K., Sarin R., Venkataramana N.K., Jalali R., Vishwanath P.N., Mohanti B.K., Tripathi R.P., Kalia V.K., Jain V. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther 2009, 5(Suppl. 1):S21-S26.
99. Singh D., Banerji A.K., Dwarakanath B.S., Tripathi R.P., Gupta J.P., Mathew T.L., Ravindranath T., Jain V. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther. Onkol 2005, 181:507-514.
100. Mohanti B.K., Rath G.K., Anantha N., Kannan V., Das B.S., Chandramouli B.A., Banerjee A.K., Das S., Jena A., Ravichandran R., Sahi U.P., Kumar R., Kapoor N., Kalia V.K., Dwarakanath B.S., Jain V. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys 1996, 35:103-111.